Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

61.30
+1.091.81%
Post-market: 61.300.00000.00%16:10 EDT
Volume:40.39K
Turnover:2.46M
Market Cap:296.69M
PE:20.05
High:61.51
Open:60.28
Low:59.85
Close:60.21
52wk High:64.10
52wk Low:44.47
Shares:4.84M
Float Shares:4.84M
Volume Ratio:0.81
T/O Rate:0.83%
Dividend:1.52
Dividend Rate:2.48%
EPS(TTM):3.06
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Revolution Medicines Signs Long-Term Headquarters Lease Agreement

TIPRANKS
·
Sep 01

Revolution Medicines (RVMD) Could Be 7% Below Fair Value On FDA Approval Of RASONQUE

Simply Wall St.
·
Sep 01

Shandong Oriental Ocean Secures Regulatory Approval for Its Scavenger Receptor-A Assay Kit

Stock News
·
Sep 01

Affordable Housing Stocks Investors Are Watching As Social Spending Moves Center Stage

Simply Wall St.
·
Sep 01

NASD Most Active Issues

Dow Jones
·
Sep 01

Axsome pullback brings attractive entry point, says H.C. Wainwright

TIPRANKS
·
Aug 31

Axsome Therapeutics, - Doses First Patient in Summit Phase 3 Trial of Axs-05 for Smoking Cessation

THOMSON REUTERS
·
Aug 31

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

GlobeNewswire
·
Aug 31

Revolution Medicines, Inc. : Needham Raises Target Price to $275 from $240

THOMSON REUTERS
·
Aug 31

Guangdong Hybribio Biotech's Subsidiary Secures In Vitro Diagnostic Device Registration Certificate

Stock News
·
Aug 31

Does Guardant Health’s (GH) Patent Appeal Reshape Its Competitive Moat More Than Its Royalty Bill?

Simply Wall St.
·
Aug 30

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)

TIPRANKS
·
Aug 29

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

Immunovant Director Atul Pande Disposes of 1,500 Common Shares Worth $64,905

Reuters
·
Aug 29

Revolution Medicines Set to Post 'Strong Launch' for Rasonque, UBS Says

MT Newswires Live
·
Aug 29

Roivant Sets Price for New Rare Disease Drug Lisraya at $35,000 a Month

Reuters
·
Aug 28

Lisraya is Commercially Available NOW - Roivant Presentation

THOMSON REUTERS
·
Aug 28

Roivant Sciences Exec Says Lisraya Will be Available at List Price of $35,000 for a 30-Day Supply

THOMSON REUTERS
·
Aug 28

Roivant Sciences Price Target Maintained with a $41.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 28

US Regulator Approves Novel Pancreatic Cancer Therapy, Marking Major Win for Independent Biotech

Deep News
·
Aug 28